NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance.

Neurosci Lett

Department of Physiology, Zhongshan Medical College, Sun Yat-sen University, 74, Zhongshan 2nd Road, Guangzhou 510080, PR China.

Published: December 2009

N-methyl-d-aspartate (NMDA) receptors and c-Jun N-terminal kinase (JNK) have been shown to be involved in morphine antinociceptive tolerance. However, whether chronic morphine-induced activation of the spinal JNK is NMDA receptor-dependent is unknown. The present study investigated the link between the spinal NMDA receptor NR2B subunit and the JNK activation during morphine antinociceptive tolerance in rats. Our results showed that chronic morphine treatment induced upregulation of the NR2B expression and activation of JNK in the spinal cord. Moreover, the increased NR2B-immunoreactivity (IR) and phosphorylated JNK-IR were observed mainly at the superficial dorsal horn laminae of the spinal cord; the spinal p-JNK was mainly expressed in astrocytes and NR2B in neurons. SP600125, a selective inhibitor of JNK, significantly attenuated morphine tolerance. MK-801, a noncompetitive NMDA receptor antagonist, not only suppressed morphine antinociceptive tolerance and the increase in NR2B, but also reduced the spinal JNK activation induced by chronic morphine treatment. These findings demonstrated for the first time that NMDA receptor-dependent activation of the spinal JNK contributes to morphine antinociceptive tolerance and that MK-801 attenuates morphine tolerance partly due to its inhibition on the spinal JNK activation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neulet.2009.10.013DOI Listing

Publication Analysis

Top Keywords

spinal jnk
20
morphine antinociceptive
20
antinociceptive tolerance
20
jnk activation
16
spinal
9
jnk
9
morphine
9
nmda receptors
8
activation morphine
8
activation spinal
8

Similar Publications

The surge in spinal cord injuries (SCI) attracted many neurobiologists to explore the underlying complex pathophysiology and to offer better therapeutic outcomes. The multimodal approaches to therapy in SCI have proven to be effective but to a limited extent. The clinical basics involve invasive procedures and limited therapeutic interventions, and most preclinical studies and formulations are yet to be translated due to numerous factors.

View Article and Find Full Text PDF

Spinal cord injury (SCI) involves a continuous and dynamic cascade of complex reactions, with mitochondrial damage and dysfunction-induced energy metabolism disorders playing a central role throughout the process. These disorders not only determine the severity of secondary injuries but also influence the potential for axonal regeneration. Given the critical role of energy metabolism disturbances in the pathology of SCI, strategies such as enhancing mitochondrial transport within axons to alleviate local energy deficits, or transplanting autologous or allogeneic mitochondria to restore energy supply to damaged tissues, have emerged as potential approaches for SCI repair.

View Article and Find Full Text PDF

In the secondary injury stage of spinal cord injury, mitochondrial dysfunction leads to decreased ATP production, increased ROS production, and activation of the mitochondria-mediated apoptosis signaling pathway. This ultimately intensifies neuronal death and promotes the progression of the injury. Apelin, a peptide produced by the APLN gene, has demonstrated promise in the treatment of spinal cord injury.

View Article and Find Full Text PDF

Intervertebral disc degeneration (IDD) serves as the underlying pathology for various spinal degenerative conditions and is a primary contributor to low back pain (LBP). Recent studies have revealed a strong correlation between IDD and biological processes such as Programmed Cell Death (PCD), cellular senescence, inflammation, cell proliferation, extracellular matrix (ECM) degradation, and oxidative stress (OS). Of particular interest is the emerging evidence highlighting the significant involvement of the JNK signaling pathway in these fundamental biological processes of IDD.

View Article and Find Full Text PDF
Article Synopsis
  • Astrocytes function as immune cells that release chemokines, specifically CCL5, which attract leukocytes to sites of spinal cord injury (SCI), leading to increased inflammation.
  • The study found that levels of CCL5 increase in parallel with HMGB1 after SCI, and blocking HMGB1 significantly lowers CCL5 levels.
  • HMGB1 activates the production of CCL5 in astrocytes through specific receptors and pathways, and inhibiting HMGB1 can reduce inflammation and improve recovery after SCI, suggesting new potential treatments for CNS inflammation.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!